Tricuspid valve replacement to reduce leaking in the heart
Part of Heart & circulation clinical trials.
This trial tests a new catheter-based procedure that replaces the tricuspid valve to reduce severe valve leaking. It may help people who still have symptoms despite heart medicines, but only if their heart shape and other health details fit the device requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe leaking of the tricuspid valve (either primary or secondary cause)
- You have symptoms despite treatment, and your walking/activity level is at least NYHA Class II (if Class IV, you must be able to walk)
- You’ve been on heart failure medicines for at least 30 days, including a water pill (diuretic)
- You’re 18 or older, and your heart team and study imaging teams say you’re a good candidate for this specific device
- You can and will follow the study visits and tests, and you can sign informed consent
- Your anatomy (heart and blood vessels) fits what the imaging team says is usable for this procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial studies a catheter-based procedure to replace the tricuspid valve in people with severe valve leakage. It aims to improve symptoms and heart function while tracking safety and effectiveness.
This trial tests a new device that replaces a leaky tricuspid valve (a heart valve) without open-heart surgery. If your tricuspid valve isn't working well and medicines haven't helped enough, this procedure might improve your heart function and symptoms.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This trial tests how well a new catheter-based valve system works for people with severe (or worse) tricuspid valve leaking who still have symptoms despite medicines. It aims to improve outcomes by treating the leaking valve without open-heart surgery, if your heart structure and overall health fit the study.
This trial tests a new device, called the Laplace TTVR System, to replace the tricuspid valve in people whose leaky valve (tricuspid regurgitation) continues to cause symptoms despite medical treatment. It may help if you have severe symptoms and are not a candidate for open-heart surgery.
Hear when a new Tricuspid Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.